Moonwalk Biosciences Patent Portfolio Analysis

Seventy million, and a two-year silence

A $70M Series B from Khosla Ventures, Eli Lilly and Gaorong Capital. Founded 2022. That is a fast climb, and Eli Lilly on the cap table means somebody with a drug discovery organisation looked at the science closely enough to write a cheque.

Now the awkward part. The most recent public filing from Moonwalk Biosciences is dated 27 February 2024, thirty-one months before this round closed. Patent applications publish roughly eighteen months after filing. So everything the company did through most of 2024, all of 2025, and into this year is simply not visible yet. The pulse on the screen is louder than the record behind it.

Nothing granted, everything pending

Four families since 2023. Zero granted. Four published and pending, all filed through WO. The granted ribbon has no width at all, because there is nothing in it. Every claim Moonwalk has written is still an argument with an examiner rather than a right.

Three of those four were filed in 2023, one in 2024. That front-loading tells you the founding science arrived as a bundle: methods for modifying nucleotide sequences, long-range methylation profiling, and the generation and use of epigenetic maps for drug discovery. A platform declared in one motion. The first of the four is close enough to allowance that it could grant at any time, with the rest expected to follow around 2026.

Nothing here is enforceable yet, and that is a statement about the calendar, not the quality.

Three names carry the whole platform

Seven inventors across four families. Justin K Valley appears on three of them. Arash Jamshidi appears on three. Rodriguez Ruben Alvarez on two. The remaining names appear once each, the usual signature of contributors pulled in for a specific assay or construct.

A portfolio with this shape is not a collection of separate bets. It is one idea, developed by a small core, split into the claim sets a filing strategy requires. That concentration cuts both ways. It means the families should read coherently, with related scope rather than scattered scope. It also means the institutional memory of why each claim is worded that way sits with very few people.

Four families against a thousand

The claims cluster in C12N, enzymes, cells and genetic engineering, and C12Q, nucleic acid assays. Over the last five years those same groups drew 1,027 families from Jiangnan University, 821 from Huazhong Agricultural University, 800 from China Agricultural University, 742 from Zhejiang University, 736 from the University of California and 579 from South China Agricultural University.

Moonwalk has four. On this scale it is a dot beside a set of spheres. That is not the insult it looks like. Agricultural genomics institutes filing at industrial volume are not writing claims about epigenetic maps for human drug discovery. But the density means scope is the only thing that matters here. In a space this full, count buys nothing and wording buys everything.

Who reads these applications already

Three organisations have cited the portfolio: Birmingham University twice, the European Molecular Biology Laboratory twice, and Jiangsu Qinke Biological Res Center once. Five citing publications in total, from applications that are barely two years published and not yet granted.

Note who those citers are not. They are not the high-volume agricultural filers that dominate the CPC group. They are a research university, a European molecular biology institute, and a biological research centre. The work is being picked up by people doing methylation and genome biology, which is the neighbourhood the claims were written for. Same-week filings in C12N15 came from Encoded Therapeutics and Cloverleaf Bio.

The citation trail points at the intended field, not the crowded one.

What the file cannot tell you yet

So here is the position. A well-funded company with a coherent four-family platform, concentrated in three inventors, in a CPC space where claim scope is the only defensible currency, with nothing granted and the first allowances expected around 2026. The published record ends in February 2024 and the hiring pattern, seven bio and clinical roles, four other, two software and AI, matches exactly the claim space already on file.

That alignment is the useful signal. A company drifting away from its filings hires against a different skill set. Moonwalk is hiring machine learning bioinformaticians and mRNA molecular biologists, which is what you staff to extend methylation profiling and epigenetic map claims rather than replace them. Expect more of the same claim space when the 2024 to 2026 filings surface.